Pediatric Nephrology

, Volume 28, Issue 8, pp 1315–1318 | Cite as

Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B

  • Rodney D. GilbertEmail author
  • Darren J. Fowler
  • Elizabeth Angus
  • Stephen A. Hardy
  • Louise Stanley
  • Timothy H. Goodship
Brief Report



Atypical haemolytic uraemic syndrome (aHUS) is caused by dysregulated complement activation. A humanised anti-C5 monoclonal antibody has recently become available for treatment of this condition


We present the first description of an infant with an activating mutation of complement factor B successfully treated with eculizumab. On standard doses she had evidence of ongoing C5 cleavage despite a good clinical response.


Eculizumab is effective therapy for aHUS associated with factor B mutations, but recommended doses may not be adequate for all patients.


Atypical haemolytic uraemic syndrome Eculizumab Complement factor B Gain-of-function mutation Complement activation 



Drs. MR Haq, A Nagra and MJ Harmer are thanked for their clinical contributions.


  1. 1.
    Loirat C, Frémeaux-Bacchi V (2011) Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 6:60CrossRefPubMedGoogle Scholar
  2. 2.
    Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJH (2010) Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 31:E1445–E1460CrossRefPubMedGoogle Scholar
  3. 3.
    Bexborn F, Andersson PO, Chen H, Nilsson B, Nilsson Ekdahl K (2008) The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol Immunol 45:2370–2379CrossRefPubMedGoogle Scholar
  4. 4.
    Joiner KA (1988) Complement evasion by bacteria and parasites. Annu Rev Microbiol 42:201–230CrossRefPubMedGoogle Scholar
  5. 5.
    Ricklin D (2012) Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy. Immunobiology 217:1057–1066CrossRefPubMedGoogle Scholar
  6. 6.
    de Jorge EG, Harris C, Esparza-Gordillo J, Carreras L, Arranz EA, Abarrategul G, López-Trascasa M, Sánchez-Corral P, Morgan BP, de Córdoba SR (2007) Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 104:240–245CrossRefGoogle Scholar
  7. 7.
    Besbas N, Gulhan B, Karpman D, Topaloglu R, Duzova A, Korkmaz E, Ozaltin F (2013) Neonatal onset hemolytic uremic syndrome successfully treated with eculizumab. Pediatr Nephrol 28:155–158CrossRefPubMedGoogle Scholar
  8. 8.
    Cavci FS, Cakar N, Hancer VS, Uncu N, Acar B, Gur G (2012) Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatr Nephrol 27:2327–2331CrossRefGoogle Scholar
  9. 9.
    Al-Akash SL, Almond PS, Savill VH Jr, Gharaybey SL, Hogue C (2011) Eculizumab induces long-term remission in recurrent post transplant HUS associated with C3 gene mutation. Pediatr Nephrol 26:613–619CrossRefPubMedGoogle Scholar
  10. 10.
    Châtelet V, Lobbedez T, Frémeaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de Ligny B (2010) Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. Transplant Proc 42:4353–4355CrossRefPubMedGoogle Scholar
  11. 11.
    Salem G, Flynn J, Cataland SR (2013) Profound neurological injury in a patient with atypical hemolytic uremic syndrome. Ann Hematol 92:557–558CrossRefPubMedGoogle Scholar
  12. 12.
    Malina M, Gulati A, Bagga A, Majid MA, Simkova E, Schaefer F (2013) Peripheral gangrene in children with atypical hemolytic uremic syndrome. Pediatrics 131:e331–e335CrossRefPubMedGoogle Scholar

Copyright information

© IPNA 2013

Authors and Affiliations

  • Rodney D. Gilbert
    • 1
    Email author
  • Darren J. Fowler
    • 2
  • Elizabeth Angus
    • 3
  • Stephen A. Hardy
    • 4
  • Louise Stanley
    • 4
  • Timothy H. Goodship
    • 5
  1. 1.Regional Paediatric Nephro-Urology UnitSouthampton Children’s HospitalSouthamptonUK
  2. 2.Department of HistopathologySouthampton General HospitalSouthamptonUK
  3. 3.Biomedical Imaging UnitSouthampton General HospitalSouthamptonUK
  4. 4.Northern Molecular Genetics Service, International Centre for LifeNewcastle upon Tyne Hospitals NHS Foundation TrustNewcastleUK
  5. 5.Institute of Genetic MedicineNewcastle University, International Centre for LifeNewcastle upon TyneUK

Personalised recommendations